Navigation Links
FDA Approval For Lucentis

The first drug proven to significantly improve the vision of elderly patients was approved by the FDA on Friday//.

The drug, Lucentis, is to treat age-related macular degeneration in its wet form, where blood vessels behind the retina leak, worsening vision and often leading to blindness. 90 percent of the 1.4 million Americans, who have lost their vision due to this degeneration, are estimated to have the wet form of the disease.

Lucentis is manufactured by Genentech, Inc., a Biotechnology Company based in South San Francisco, California. None of the other Food and Drug Administration (FDA)-approved treatments has been shown to significantly reverse vision deterioration, like Lucentis does. Lucentis cost $1,950 per injection, and should be used monthly or bimonthly.

Lucentis and Avastin, another Genentech cancer drug, block the same protein believed to instigate blood vessel growth. Dr. Hal Barron, Genentech chief medical officer said, "We believe Lucentis is a much better choice. I really believe when treating patients, you have to look at the wealth of data supporting its use and the quality of that data."

The FDA has not granted sanction for Avastin to be used in treating macular degeneration.

The National Eye Institute, part of the National Institutes of Health, has received an outside proposal to conduct a comparative study on Avastin and Lucentis in treating AMD.

The anticipated cost of Lucentis may limit its usage, while Avastin is far cheaper.

Neither drug is a complete cure for age-related macular degeneration.

The most commonly reported side- effects of Lucentis include conjunctival hemorrhage, eye pain, floaters, increased eye pressure and inflammation.


'"/>




Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Approval For Lucentis

(Date:5/16/2008)...edicine is in a precipitous decline, David C. Dale...hysicians (ACP), today joined with leading repres...ll for comprehensive reforms to attract, recruit a...e physicians. , During a panel discussion of th...Dale and other panelists spoke about the challenge...
(Date:5/16/2008)...wswire/- "Huh, what did you,say?" is a phrase bein...hildren. More than 30 million Americans, that is 1...nd the numbers are growing at a dramatic rate.,Thi...me form of hearing,loss. An effort to bring more a...at led Kathlyn Maguire, who has profound hearing l...
(Date:5/16/2008)...Million for Life-threatening,Disease, BETHESDA, M...early,every state will raise funds for cystic fibr...ting in GREAT STRIDES, the largest national CF,fun... today., May is National Cystic Fibrosis Awarenes...etic disease that causes fatal lung infections and...
(Date:5/16/2008)...10,000 Sensual O Condom Packs Donation Marks the ... LOS ANGELES, May 16 /PRNewswire/ -- On Saturday, ...wn best for his hit song "Everybody in the Club,Ge...Institute (UHI) with,10,000 Sensual O Vibrating Co...ng made to promote the launch of the Association f...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Everybody in the Club Scream O! 2
... interesting study it was found that older women s...felong viral infection- acquired early in life) we...g frail than those who did not have the infection.... Geriatrics Society. This is the first time an ass...
...major breakthrough the British scientists have rep...n cells from stem cells. Professor Harry Moore fro...id that "the research meant it might ultimately be... use in assisted conception treatments". It should...
...ons prefer complete revascularization technique to...bypass surgery. The procedure is said to increase ... surgery. Surgeons from Cedars-Sinai Medical Cente...d blockages in multiple of coronary arteries have ...
...ren who are being diagnosed for diabetes type 2 ma...ric illness at the onset of the disease. A study d...of Philadelphia have shown that among the children...type 2 disease, two out of five of them have showe...
Other Medicine News:
(Date:5/15/2008)...mount of research reflects depth and breadth of, ...lop new treatments for dive...ht impact of Zometa(R), the leading IV, bisphospho... breast cancer, - Four oral sessions to feature R... of mTOR, including first results of RECORD-1 stud...
(Date:5/15/2008)...d TOULOUSE, France, May 15 /- Cerenis...aceutical company,developing HDL-related compounds... diseases, today announced that it has completed a...mpany,s lead product candidates.,CER-002 is a pero...a-specific agonist in development for the treatmen...
(Date:5/15/2008)...y Remains for an Antiplatelet Therapy that, Combin...mbination of Plavix/Iscover and Aspirin, Accor...THAM, Mass., May 15 /- Decision Resou...sory firms for pharmaceutical and,healthcare issue...ffers,improvement in patient compared to Sanofi-Av...
(Date:5/15/2008)...y 15 /- Omega 3 fatty acids bound to,... a credible natural,alternative and may have benef...nt in vivo French study reveals. While several stu...n hyperactivity, French researchers have,hypothesi... effects on,impulse control., These research find...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 1Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 2Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 3ADVENTRX Pharmaceuticals to Present at the Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5333 1Chiltern Announces New Expansion in Portugal 19137 1Chiltern Announces New Expansion in Portugal 19137 2Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2
...a from XL880, Phase II data from XL999 studies,sch...ns -, SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswir...t data from clinical trials of,the company,s inves...nted at the 2007 American Society of Clinical Onco...ne 1 to 5 in Chicago,Illinois. , , -- Data fro...
...y 31, 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceu...day that,it has completed patient treatment in the...ial of C1-esterase inhibitor (C1-INH) for,heredita...d CHANGE,examined and evaluated the efficacy and ...cute HAE attacks and as,prophylactic treatment to ...
Other Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 3Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 4
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std.
Cholesterol/HDL with 200 tests.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl.
Medicine Products: